Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
Pharmacogenomics J
; 20(5): 724-735, 2020 10.
Article
in En
| MEDLINE
| ID: mdl-32042096
Full text:
1
Database:
MEDLINE
Main subject:
Platelet Aggregation Inhibitors
/
Drug Costs
/
Molecular Diagnostic Techniques
/
Acute Coronary Syndrome
/
Percutaneous Coronary Intervention
/
Cytochrome P-450 CYP2C19
/
Pharmacogenomic Variants
Type of study:
Diagnostic_studies
/
Guideline
/
Health_economic_evaluation
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Pharmacogenomics J
Journal subject:
BIOLOGIA MOLECULAR
/
FARMACOLOGIA
Year:
2020
Type:
Article
Affiliation country:
United States